1. Value-based differential pricing: efficient prices for drugs in a global context;Danzon;Health Econ,2013
2. National Organization for Rare Disorders. Orphan drugs represent 41 percent of all new medications. Available from: https://rarediseases.org/orphan-drugs-represent-41-percent-of-all-new-medications-approved-by-fda-in-2016/.
3. The special case of gene therapy pricing;Brennan;Nat Biotechnol,2014
4. Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value;Marsden,2017